Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections

[1]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[2]  L. Hydo,et al.  INCIDENCE AND CONSEQUENCES OF MULTIPLE ORGAN DYSFUNCTION SYNDROME AFTER ABDOMINAL AORTIC RECONSTRUCTION , 1994 .

[3]  R. Sauerwein,et al.  Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. , 1994, The Journal of infectious diseases.

[4]  M. Guenounou,et al.  Involvement of tumor necrosis factor alpha in intracellular multiplication of Legionella pneumophila in human monocytes , 1993, Infection and immunity.

[5]  C. Dinarello,et al.  Cytokine Measurements in Septic Shock , 1993, Annals of Internal Medicine.

[6]  D. Gouma,et al.  Influence of nephrectomy on tumor necrosis factor clearance in a murine model. , 1993, Journal of immunology.

[7]  P. Brandtzaeg,et al.  Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. , 1992, Microbial pathogenesis.

[8]  M. van Deuren,et al.  Cytokines and the response to infection , 1992, The Journal of pathology.

[9]  R. Sauerwein,et al.  Plasma and whole blood exchange in meningococcal sepsis. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Dinarello,et al.  Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Suter,et al.  Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. , 1992, Immunology.

[13]  P Franchimont,et al.  Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. , 1992, Annals of surgery.

[14]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[15]  C. Dinarello,et al.  Production of interleukin-1-receptor antagonist during experimental endotoxaemia , 1991, The Lancet.

[16]  W. Arend.  Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. , 1991, The Journal of clinical investigation.

[17]  C. Dinarello,et al.  Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. , 1991, Blood.

[18]  C. Dinarello.  The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. , 1991, The Journal of infectious diseases.

[19]  J. Norton,et al.  A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice , 1991, The Journal of experimental medicine.

[20]  U. Gullberg,et al.  A tumor necrosis factor binding protein (TNF-BP)-physiological antagonist of TNF , 1991, Biotherapy.

[21]  H. Holtmann,et al.  Soluble and cell surface receptors for tumor necrosis factor. , 1991, Agents and actions. Supplements.

[22]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[23]  T. van der Poll,et al.  Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.

[24]  J. Schellekens,et al.  Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock , 1990 .

[25]  J. Murray,et al.  Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. , 1990, The American review of respiratory disease.

[26]  R. Tompkins,et al.  Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. , 1990, The Journal of infectious diseases.

[27]  M. Lamy,et al.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. , 1989, Critical care medicine.

[28]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[29]  W. Buurman,et al.  Plasma tumor necrosis factor and mortality in critically ill septic patients. , 1989, Critical care medicine.

[30]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[31]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[32]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[33]  T. Klein,et al.  Protective Effects of Tumor Necrosis Factor in Experimental Legionella pneumophila Infections of Mice via Activation of PMN Function , 1988, Journal of leukocyte biology.

[34]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[35]  K. Tracey,et al.  Cytokine appearance in human endotoxemia and primate bacteremia. , 1988, Surgery, gynecology & obstetrics.

[36]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[37]  E. A. Havell.  Production of tumor necrosis factor during murine listeriosis. , 1987, Journal of immunology.

[38]  J. Gabrilove,et al.  Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[40]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[41]  O. Rekvig,et al.  Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. , 1984, British medical journal.